Cumberland Pharmaceuticals reports 2023 earnings
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company located in Nashville, has announced that its product portfolio of Food and Drug Administration-approved brands delivered combined revenues of $40 million in 2023 and provided $6 million in cash generated from operations.
Cumberland reported that it ended the year with $82 million in total assets – including $18 million in cash, $53 million in liabilities, and $30 million of shareholders’ equity.
“In many ways 2023 was a building year for Cumberland, as we continued to integrate our newest products, while also delivering several significant achievements,” said A.J. Kazimi, Cumberland Pharmaceuticals Chief Executive Officer. “We were pleased to expand the labeling for our Caldolor® product to include use in infants, while continuing to build our other brands and progress our clinical programs.”
In addition to Caldolor®, the company’s portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
- Omeclamox®-Pak, (omeprazole, clarithromycin, amoxicillin) oral, for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
- Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Cumberland Pharmaceuticals, which describes itself as the largest biopharmaceutical company founded and headquartered in Tennessee, is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
